Lilly’s GLP-1 Pill: A Weight-Loss Revolution?
Archyde Eli Lilly’s Oral Obesity Drug Shows Promise, Stock Surges april 18, 2025 Eli Lilly’s stock experienced a significant surge following the release of positive Phase 3 trial results for its experimental oral obesity drug, Orfoglipron. The data suggests a potential shift in how obesity and diabetes are treated, offering a convenient alternative to injectable … Read more